Villalón C M, Sánchez-López A, Centurión D
Departamento de Farmacología y Toxicología, CINVESTAV, I.P.N., México D.F., México.
Naunyn Schmiedebergs Arch Pharmacol. 1996 Nov;354(5):550-6. doi: 10.1007/BF00170827.
It has recently been shown that the external carotid vasoconstrictor response to 5-HT in the dog is primarily mediated by sumatriptan-sensitive 5-HT1-like receptors; however, the fact that these receptors are not blocked by metergoline, a 5-HT1D ligand, raises questions about their possible correlation with the 5-HT1D receptor subtype. Since a number of drugs display high affinity for the 5-HT1D (GR127935) and 5-HT1F (e.g. methysergide and oxymetazoline) receptor subtypes, in this study we have used these drugs to determine whether the above vasoconstrictor 5-HT1-like receptors correlate with the 5-HT1D and/or 5-HT1F receptor subtypes. One-minute intracarotid infusions of 5-HT (0.3-30 micrograms/min), sumatriptan (1-30 micrograms/min), oxymetazoline (0.03-3 micrograms/min) and noradrenaline (0.3-3 micrograms/min) resulted in dose-dependent decreases in external carotid blood flow without changes in arterial blood pressure or heart rate. These vasoconstrictor responses remained unaltered after i.v. administration of physiological saline (0.015, 0.05 and 0.15 ml/kg; n = 4) or ritanserin (1 mg/kg; n = 5). In contrast, GR127935 (1, 3 and 10 micrograms/kg, n = 6) potently blocked the responses to 5-HT (unmasking a dose-dependent vasodilator component) and sumatriptan without affecting those to oxymetazoline or noradrenaline. Interestingly, methysergide (10, 30 and 100 micrograms/kg, n = 5) also blocked the vasoconstrictor responses to 5-HT and sumatriptan, but unlike GR127935, did not revert the vasoconstrictor response to 5-HT; the responses to oxymetazoline remained unaffected, but those to noradrenaline were apparently attenuated by the highest dose. Taken together, the above findings suggest that the sumatriptan-sensitive 5-HT1-like receptors mediating canine external carotid vasoconstriction resemble 5-HT1D receptors, probably of the 5-HT1D beta subtype on the basis of the resistance to blockade by ritanserin. The pharmacological profile of these receptors could be similar (bovine and human cerebral arteries, porcine carotid arteriovenous anastomoses and human coronary arteries) to other putative 5-HT1D receptors mediating vascular responses.
最近的研究表明,犬颈外动脉对5-羟色胺(5-HT)的血管收缩反应主要由对舒马曲坦敏感的5-HT1样受体介导;然而,这些受体未被5-HT1D配体美替拉酮阻断,这一事实引发了关于它们与5-HT1D受体亚型可能相关性的疑问。由于许多药物对5-HT1D(GR127935)和5-HT1F(如麦角新碱和羟甲唑啉)受体亚型具有高亲和力,在本研究中我们使用这些药物来确定上述血管收缩性5-HT1样受体是否与5-HT1D和/或5-HT1F受体亚型相关。颈内动脉内输注1分钟的5-HT(0.3 - 30微克/分钟)、舒马曲坦(1 - 30微克/分钟)、羟甲唑啉(0.03 - 3微克/分钟)和去甲肾上腺素(0.3 - 3微克/分钟)导致颈外动脉血流量呈剂量依赖性减少,而动脉血压和心率无变化。静脉注射生理盐水(0.015、0.05和0.15毫升/千克;n = 4)或利坦色林(1毫克/千克;n = 5)后,这些血管收缩反应保持不变。相比之下,GR127935(1、3和10微克/千克,n = 6)能有效阻断对5-HT(揭示出剂量依赖性血管舒张成分)和舒马曲坦的反应,而不影响对羟甲唑啉或去甲肾上腺素的反应。有趣的是,麦角新碱(10、30和100微克/千克,n = 5)也能阻断对5-HT和舒马曲坦的血管收缩反应,但与GR127935不同的是,它不会使对5-HT的血管收缩反应逆转;对羟甲唑啉的反应保持不受影响,但对去甲肾上腺素的反应在最高剂量时明显减弱。综上所述,上述发现表明,介导犬颈外动脉血管收缩的对舒马曲坦敏感的5-HT1样受体类似于5-HT1D受体,基于对利坦色林阻断的抗性,可能是5-HT1Dβ亚型。这些受体的药理学特征可能与介导血管反应的其他假定的5-HT1D受体(牛和人的脑动脉、猪的颈动脉动静脉吻合处和人的冠状动脉)相似。